Vanguard Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
|
|||||
|
2024
Q2 | $293M | Sell |
|
|||||
|
2024
Q1 | $315M | Buy |
|
|||||
|
2023
Q4 | $313M | Buy |
|
|||||
|
2023
Q3 | $139M | Buy |
|
|||||
|
2023
Q2 | $180M | Sell |
|
|||||
|
2023
Q1 | $149M | Buy |
|
|||||
|
2022
Q4 | $190M | Buy |
|
|||||
|
2022
Q3 | $166M | Buy |
|
|||||
|
2022
Q2 | $133M | Buy |
|
|||||
|
2022
Q1 | $168M | Buy |
|
|||||
|
2021
Q4 | $156M | Buy |
|
|||||
|
2021
Q3 | $138M | Buy |
|
|||||
|
2021
Q2 | $90.3M | Buy |
|
|||||
|
2021
Q1 | $44.3M | Buy |
|
|||||
|
2020
Q4 | $52.2M | Buy |
|